# A5 ADVERSARY / COMPLETENESS AUDIT — GAUDIUMIVF Q1 FY27

Auditor: A5 ADVERSARY (Opus 4.8). Fresh context: A4 review + A1 extract + A2 ledger only.
Every number below re-derived from `extract_results_gaudiumivf_q1fy27.txt` raw Lakh figures
(÷100 to Cr). A4/A3 cites checked, not deferred to.

---

## AUDIT 0 — DELIVERABLE-COMPLETENESS (HARD GATE)

Plain-Language Brief present at review lines 531-614. All four labelled parts present, non-empty,
real content (not placeholder):

| Part | Heading | Lines | Status |
|---|---|---|---|
| 1. Summary narrative | "### 1. Summary narrative" | 533-554 (~20 lines) | PRESENT |
| 2. Sector intelligence | "### 2. Sector intelligence" | 556-573 | PRESENT |
| 3. Business-model intelligence | "### 3. Business-model intelligence" | 576-596 | PRESENT |
| 4. Competition intelligence | "### 4. Competition intelligence" | 598-614 | PRESENT |

Provenance tags (this-filing vs general-knowledge vs prior-run) are carried in parts 2-4, which
is the correct discipline for a pre-position name. GATE 0: PASS.

---

## AUDIT 1 — COVERAGE (fresh enumeration vs A2 ledger)

Independent grep/sweep over the extract reproduces every A2 category count exactly:

| Category | A2 count | My fresh count | Orphan rows | Status |
|---|---|---|---|---|
| Board-outcome agenda items (L42,47,53,71,76) | 5 | 5 | none | MATCH |
| Numbered notes (SA N1/7/8 + Consol N1/7/8) | 6 | 6 | none | MATCH |
| Unnumbered Note-1 sub-items (7 SA + 7 Consol) | 14 | 14 | none | MATCH |
| Auditor paras (SA 6 + Consol 7) | 13 | 13 | none | MATCH |
| Entities in consolidation | 3 | 3 | none | MATCH |
| Standalone P&L line items (217-264) | 24 | 24 | none | MATCH |
| Consolidated P&L line items (503-576) | 25 | 25 | none | MATCH |
| IPO utilisation table (×2 stmts) | 12 | 12 | none | MATCH |
| Note 7 >10%-expenditure (×2 stmts) | 6 | 6 | none | MATCH |
| Annexure D header fields | 12 | 12 | none | MATCH |
| Annexure D objects table | 6 | 6 | none | MATCH |
| Annexures (A label missing, content present) | 4 | 4 | none | MATCH |
| Signature blocks | 5 | 5 | none | MATCH |
| ZERO_STANDING flagged rows | 15 | 15 | none | MATCH |

No row my fresh pass found is absent from the ledger (nothing to return to A2). No ledger row is
absent from A4: A4's LEDGER-RECONCILIATION PREAMBLE (review L24-38) enumerates every companion
category and asserts 100% reconciliation, and each material row is individually surfaced (OI/FD
interest, discontinued/EKK, subsidiary margin, IPO capex, GCP reallocation, prior-year tax,
board outcome, comparative-hygiene, UDIN/Annexure-A). No orphan row → no return to A3.

Soft observation (NOT a gate failure): board agenda item 2 (Internal Auditor re-appointment,
Ram Rattan & Associates / Annexure B, ledger §1 row 2 and §6 row B) is not individually named in
A4's body; it is captured only under the blanket "5 board-outcome agenda items reviewed"
reconciliation. The ledger itself flags this row "—" (no finding), it is a routine annual
re-appointment requiring no shareholder action and carrying no forensic content, and the material
governance item (secretarial-auditor ratification, agenda item 3 / Annexure C) IS carried into
Monitorables. This meets the "reviewed, no finding" bar via the reconciliation preamble. Noted
for completeness, not failed.

A3 forensic coverage (re-derived independently from the extract, not from A3's reasoning which
A5 does not see): every adversarial item the extract independently yields is carried into A4 —
FD-interest concentration (L297/619), discontinued-op/EKK stale listing (L452, 552-554),
subsidiary net-margin collapse (consol-minus-SA PAT gap), IPO capex 2% deployed (L325), GCP
reallocation (L919-934), Q4FY26 prior-year tax credit (L242/543), identical Q1FY26 legal fees
SA=Consol Rs.140.27L (L355/676), Annexure-A label missing (L45 vs body), both UDINs garbled
(L206/492). No independently-derivable forensic item is missing from A4. COVERAGE: PASS.

---

## AUDIT 2 — ARITHMETIC (recomputed from raw Lakh figures)

Spot-recomputed every derived cell in Steps 1A-derived, 1B-derived, 2A, 2B, 4A, 4B, and the
YAML sc_gap block. Representative checks (all Lakh-precise, then ÷100):

| Metric | A4 value | Recomputed | Source line | Status |
|---|---|---|---|---|
| SA Op EBITDA Q1FY27 (PBT+D+Fin−OI) | 2.17 | 229.96+67.54+32.26−112.36 = 217.40L = 2.17 | 236/233/232/223 | MATCH |
| SA Op EBITDA margin Q1FY27 | 15.90% | 217.40/1367.73 = 15.90% | 222 | MATCH |
| SA Op EBITDA margin Q1FY26 | 33.86% | 415.55/1227.32 = 33.86% | 222 | MATCH |
| SA Core PBT ex-OI Q1FY27 | 1.18 | 229.96−112.36 = 117.60L = 1.18 | 236/223 | MATCH |
| SA OI/PBT Q1FY27 | 48.86% | 112.36/229.96 = 48.86% | 223/236 | MATCH |
| SA ETR Q1FY27 | 27.66% | 63.61/229.96 = 27.66% | 244/236 | MATCH |
| SA Revenue YoY | +11.44% | 1367.73/1227.32−1 = 11.44% | 222 | MATCH |
| SA Op EBITDA YoY | −47.68% | 217.40/415.55−1 = −47.68% | — | MATCH |
| SA Op EBITDA margin YoY bps | −1,796 | 3386−1590 = 1,796 bps | — | MATCH |
| SA Core PBT ex-OI YoY | −61.80% | 117.60/307.84−1 = −61.80% | — | MATCH |
| SA EBIT(op) YoY | −58.08% | 149.86/357.53−1 = −58.08% | — | MATCH |
| SA S&M YoY | +140% | 382.96/159.72−1 = +139.77% | 349 | MATCH |
| Consol Op EBITDA Q1FY27 | 2.42 | 244.98+72.17+37.62−112.36 = 242.41L = 2.42 | 537/531/529/514 | MATCH |
| Consol Op EBITDA margin Q1FY27 | 12.51% | 242.41/1937.66 = 12.51% | 512 | MATCH |
| Consol Core PBT ex-OI Q1FY27 | 1.33 | 244.98−112.36 = 132.62L = 1.33 | 537/514 | MATCH |
| Consol Core PBT ex-OI YoY | −67.24% | 132.62/404.78−1 = −67.24% | — | MATCH |
| Consol Op EBITDA margin YoY bps | −1,651 | 2902−1251 = 1,651 bps | — | MATCH |
| Consol PAT(continuing) YoY | −42.27% | 177.59/307.62−1 = −42.27% | 549 | MATCH |
| Consol S&M YoY | +148% | 404.33/162.72−1 = +148.48% | 670 | MATCH |
| SA PAT bridge sum | −0.69 | −198.15−9.52+17.43+112.36+9.15 = −68.73L = −0.69 | — | MATCH |
| Consol PAT bridge sum | −1.30 | −272.87−11.41+12.12+112.36+29.77+0.24 = −129.79L = −1.30 | — | MATCH |

Standalone-vs-consolidated PAT-gap math (YAML sc_gap_pat_pct), recomputed from continuing PAT:

| Period | consol−SA (A4) | Recomputed | pct-of-SA-PAT (A4) | Recomputed | Status |
|---|---|---|---|---|---|
| Q1FY26 | 0.73 | 307.62−235.08 = 72.54L = 0.73 | 30.86% | 72.54/235.08 = 30.86% | MATCH |
| Q4FY26 | 0.63 | 835.74−773.14 = 62.60L = 0.63 | 8.10% | 62.60/773.14 = 8.10% | MATCH |
| Q1FY27 | 0.11 | 177.59−166.35 = 11.24L = 0.11 | 6.76% | 11.24/166.35 = 6.76% | MATCH |
| FY26 | 2.20 | 2448.85−2228.77 = 220.08L = 2.20 | 9.87% | 220.08/2228.77 = 9.87% | MATCH |

Subsidiary net-margin claim (QfM Q5 / business-model brief) verified: subsidiary revenue
Q1FY27 = 1937.66−1367.73 = 569.93L (~Rs.570L), Q1FY26 = 1775.59−1227.32 = 548.27L; net margin
72.54/548.27 = 13.2% → 11.24/569.93 = 1.97%, i.e. "~13% to ~2%" — MATCH. Consol-minus-SA drug
purchases Q1FY27 = 707.37−92.35 = 615.02L = Rs.6.15 Cr — MATCH. IPO capex 102.95/5000 = 2.06%
("2% deployed", "Rs.48.97 Cr unspent") — MATCH. Unspent total 5611.56L = Rs.56.12 Cr — MATCH.
FD interest 102.24/112.36 = 91.0% of Q1FY27 OI — MATCH. Share-count reconciliation
(3639.34−3069.72)/5 = 113.92L shares vs fresh issue 1,13,92,500 — MATCH (rounding).

No mismatch above rounding found anywhere. ARITHMETIC: PASS.

---

## AUDIT 3 — ADVERSARIAL READ (three most-positive claims, strongest bear from same text)

**Claim 1 (review L546-547, L451): "The balance sheet is clean — net cash, debt fully repaid,
~Rs.56 Cr unspent cash; clean on solvency."**
Bear: the Rs.56 Cr is undeployed IPO money, not earned strength; 98% of new-centre capex is idle
5 months post-listing (L325), and the FD interest it throws off is ~49% of reported PBT. No
balance sheet is filed at Q1, so receivables/payables/pledge/contingent liabilities are all ND —
"clean" rests on the debt-repayment note (L921-923) and IPO table only, not a reviewed balance
sheet. COUNTER SURVIVES. Disposition: **already grafted** — A4 explicitly says net cash
"concentrates return-on-capital risk," names every ND balance-sheet row (Step 5), and caps the
verdict. No new addition required.

**Claim 2 (review L252-254): "Other-income concentration is transient by construction and decays
as the capex deploys" (reassuring framing).**
Bear: both deployment paths hurt reported PAT. Slow deployment → interest persists alongside the
62-67% core-operating decline; fast deployment → interest vanishes and reported PAT falls toward
the ~Rs.0.55 Cr SA / ~Rs.0.66 Cr consol ex-OI run-rate before any new-centre revenue matures — a
near-term earnings air-pocket. "Transient by construction" is not automatically benign. COUNTER
SURVIVES. Disposition: **already grafted** — A4 states the ex-OI run-rate PAT as the explicit
"bear-case anchor" (Step 4C) and pre-commits underwriting to core operating PBT (Step 8B).

**Claim 3 (review L224, 2C-1): "Revenue grew YoY (+11.44% SA / +9.13% consol)."**
Bear: revenue grew only ~11% while S&M rose +140%/+148% and after a Rs.90 Cr raise — deeply
negative incremental revenue per marketing rupee; consol growth (9%) trails standalone (11%),
so the subsidiary is flat-to-shrinking; and the Q1FY26 base is auditor-UNREVIEWED
(management-compiled, para 5, L179-181/466-469), so even "growth" sits on an unaudited base.
COUNTER SURVIVES. Disposition: **already grafted** — A4 foregrounds the S&M-vs-revenue disconnect
as the central interpretive point and flags the unreviewed comparative throughout.

All three strongest bears survive from the extract; all three are already materially present in
A4's review. No surviving bear counter is missing → no loop-back to A4 on adversarial grounds.

---

## PROTOCOL COMPLIANCE CHECKS

- Cash-conversion INDETERMINATE cap: A4 sets cash_conversion = INDETERMINATE (Q1, no cash-flow
  statement filed — confirmed: extract carries no CFO/balance-sheet) and caps protocol_verdict at
  PROCEED WITH CAVEATS with missing evidence named (Step 5). Correctly applied. PASS.
- No exit PE / no valuation introduced: Step 7 records only NO PRIOR / indicative first-read
  inputs, explicitly asserts "No exit PE is asserted (Section 1B v3.3 is the sole authority)."
  ROCE ~20-22% is flagged indicative and deferred to Role 1. Complies with CLAUDE.md NEVER rule.
  PASS.
- Questions-for-Management covers every AMBIGUOUS/FORWARD-SIGNAL finding: F2 (AMBIGUOUS,
  subsidiary) → Q5; FORWARD-SIGNAL F1b/F6a → Q1/Q2/Q3; F6b/F13 → Q4; F15 → Q6; F14 → Q7. Every
  such finding produces at least one row. PASS.
- Standalone-vs-consolidated PAT-gap math: recomputed above, all four periods MATCH. PASS.

---

## VERDICT

**COMPLETE.** Gate 0 passes (all four brief parts present). Coverage: no orphan rows, nothing
missing from the ledger. Arithmetic: every derived metric, YoY/QoQ, PAT bridge, and SA-vs-consol
gap re-derived from raw Lakhs with zero mismatch above rounding. Adversarial: the three strongest
surviving bears are already incorporated in A4. Cash-conversion cap, no-valuation rule, and
QfM coverage all satisfied. Proceeds to Notion save.

loop_back_to: none.

```yaml
stage: A5-adversary
company: "GAUDIUMIVF"
quarter: "q1fy27"
model: claude-opus-4-8
status: complete
verdict: COMPLETE
plain_language_brief:
  narrative: present
  sector: present
  business_model: present
  competition: present
coverage:
  orphan_rows: []
  missing_from_ledger: []
arithmetic_mismatches: []
surviving_bear_counters: []
loop_back_to: ""
gap: ""
```
